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Serum fibroblast growth factor-23 levels predict the future re-
fractory hyperparathyroidism in dialysis patients.
Background. Secondary hyperparathyroidism is a common
complication among long-term dialysis patients. The method of
predicting future parathyroid function has not yet been estab-
lished. Fibroblast growth factor-23 (FGF-23) is a newly found
humoral phosphaturic factor.
Methods. One hundred and three nondiabetic dialysis pa-
tients whose plasma intact parathyroid hormone (PTH) levels
were below 300 pg/mL were included in the study. Blood sam-
ples were stored at −80◦C for 2 years. Meanwhile, each physi-
cian in charge decided upon the strategy of medical therapy
for maintaining intact PTH levels between 150 and 300 pg/mL.
Patients were judged 2 years after the sample collection with
regard to whether the hyperparathyroidism responded to the
medical therapy. The definition of refractory secondary hy-
perparathyroidism was either (1) retaining intact PTH levels
greater than 300 pg/mL 2 years after sample collection, or (2)
having received the parathyroid intervention therapy during
the observation period. Serum FGF-23 levels were determined
with a sandwich enzyme-linked immunosorbent assay system
that detects biologically active human FGF-23.
Results. Seventeen patients with intact PTH levels greater
than 300 pg/mL were judged as having secondary hyperparathy-
roidism refractory to medical therapy. A stepwise regression
analysis revealed that only serum levels of FGF-23 were sig-
nificantly related to the prognosis of parathyroid function. A
receiver-operated characteristic analysis demonstrated that the
area under the curves obtained from FGF-23 (7099.9) was sig-
nificantly greater than that obtained from intact PTH (6306.4,
P < .01) and Ca×Pi (5670.3, P <.0001). Although the plasma in-
tact PTH levels at the beginning of the observation period were
comparable to each other, the intact PTH levels at 2 years after
the sample collection were significantly higher in the patients
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with FGF-23 ≥7500 ng/L than in those with FGF-23 <7500 ng/L
(P < .0001).
Conclusion. Serum FGF-23 level was found to be the most
useful factor in predicting future development of refractory
secondary hyperparathyroidism in long-term dialysis patients
with mild secondary hyperparathyroidism. The measurement
of serum FGF-23 levels is a promising laboratory examination
that can be applied in the clinical practice of uremic secondary
hyperparathyroidism.
Secondary hyperparathyroidism is a common compli-
cation among long-term dialysis patients. Medical ther-
apies including active vitamin D agents are effective
in most cases of early secondary hyperparathyroidism.
However, resistance to medical therapy occurs in cases
with developed hyperparathyroidism through changes in
the biological properties of parathyroid cells [1–4].
It is difficult to predict the future development of
hyperparathyroidism. The treatment strategy is there-
fore determined experientially with regard to present
parathyroid function and serum calcium levels in daily
clinical practice. However, aimlessly continuing medi-
cation in patients with secondary hyperparathyroidism
resistant to the therapy seems to worsen their prog-
nosis through its unfavorable effects on calcium and
phosphate metabolism [5]. Instead of the continuation
of medical therapy, the parathyroid intervention thera-
pies, including surgical parathyroidectomy, should be ap-
plied in such patients as soon as possible. Thus, predict-
ing the future development of secondary hyperparathy-
roidism and its resistance to medical therapy would be a
very useful indicator in the clinical treatment of dialysis
patients.
In this regard, the ultrasonic image analysis of parathy-
roid glands is a promising method for diagnosing present
resistance to medical therapy [6, 7]. However, image anal-
ysis may not be an adequate predictor of the future
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development of secondary hyperparathyroidism, espe-
cially in patients with mild secondary hyperparathy-
roidism. Moreover, the accuracy of the data obtained
from ultrasonic images largely depends on the skill of
the operators. If data obtained from serum/plasma sam-
ples can successfully predict the prognosis, this method
can be applied in most dialysis units.
Circulating factors may affect the bone and mineral
metabolism in uremic patients. The serum levels of fi-
broblast growth factor-23 (FGF-23), a newly found phos-
phaturic factor [8, 9], have been reported to be correlated
with Ca × Pi products [10], but the clinical significance of
this correlation remains unknown.
We therefore measured the levels of circulating factors
that would be related to bone and mineral metabolism,
and compared them with the clinical course in long-term
dialysis patients. The aim of the present study was to iden-
tify the serum/plasma indicators that predict the future
development of secondary hyperparathyroidism resistant
to medical therapy.
METHODS
Patients and protocol
One hundred and three nondiabetic patients who had
been undergoing maintenance hemodialysis therapy for
more than 10 years at Sumiyoshi Clinic Hospital (Mito,
Japan), Omori Clinic (Niigata, Japan), or Santo Clinic
(Niigata, Japan), and whose plasma intact parathyroid
hormone (PTH) levels were below 300 pg/mL were ini-
tially identified as subjects for the present study. These
patients received hemodialysis therapy thrice weekly, no
less than 4 hours at each session. None of them had
received kidney transplantation, continuous ambulatory
peritoneal dialysis, or parathyroid intervention therapy
before enrollment in the study.
This study was designed according to the Helsinki Dec-
laration, and was approved by the ethics committees in
each dialysis unit. Informed consent was obtained from
each patient both before sample collection and before
sample analysis.
Blood samples were collected at 9:00 a.m. on the
third day after the last dialysis session in fasting con-
dition. The samples were immediately separated into
sera and plasma, and stored at −80◦C for 2 years. The
drug washout period was not set before sample collec-
tion. Thereafter, patients were observed in the same
dialysis unit for 2 years. The calcium concentration of
the dialysate was 3.0 mEq/L. Meanwhile, each physi-
cian in charge selected the strategy of medical therapy to
maintain intact PTH levels between 150 and 300 pg/mL,
serum Ca levels <10.5 mg/dL, and Pi levels <7.5 mg/dL.
Active vitamin D agents, including alfacalcidol (0.25–
0.5 lg/day orally), calcitriol (0.25–0.5 lg/day orally or
Table 1. Summary of the clinical features of 17 patients who would be
judged to have refractory secondary hyperparathyroidism and 86
patients with medically controllable secondary hyperparathyroidism
Gender Age HD Primary
N M : F years years diseases
Refractory 17 14 : 3 53.0 ± 9.7 16.8 ± 5.3 CGN: 10
NSc: 1
Others: 2
Unknown: 4
Controllable 86 52 : 34 55.8 ± 10.2 16.2 ± 5.0 CGN: 57
NSc: 3
Others: 8
Unknown: 18
Abbreviations are: CGN, chronic glomerulonephritis; NSc, nephrosclerosis.
There were no significantly different features between these patient groups.
0.5–1.0 lg/day × 3/week intravenously), and maxacalci-
tol (5.0–15.0 lg/day × 3/week intravenously) were used
according to each patient’s condition. Calcium carbonate
was the only phosphate binder used.
Each patient was judged 2 years after sample collec-
tion with regard to whether the patient’s secondary hy-
perparathyroidism had responded or was resistant to the
medical therapy. The definition of refractory secondary
hyperparathyroidism was either (1) retaining intact PTH
levels greater than 300 pg/mL at 2 years after sample col-
lection, or (2) having received the parathyroid interven-
tion therapy [11], including surgical parathyroidectomy,
during the observation period. It was allowed to perform
parathyroid intervention therapies if plasma intact PTH
levels were more than 300 pg/mL, and other clinical symp-
toms persisted that were not safely relieved by medical
therapy any more.
Measurement of serum parameters
Thereafter, stored serum and plasma samples were an-
alyzed, and the data obtained from the samples were com-
pared with the clinical course. Measured serum calcium
levels (Ca) were adjusted with albumin levels as follows:
Ca = measured Ca levels + [4.0- albumin levels (g/dL) ×
0.8] mg/dL. Corrected serum calcium is given throughout
the paper. Plasma intact PTH levels were measured with a
two-site immunoradiometric method (Nichols Institute,
San Juan Capistrano, CA, USA). The interassay varia-
tion in the normal and elevated concentration range was
<10%. Serum bone-specific alkaline phosphatase (bAP)
and intact osteocalcin (OC) were measured by enzyme
immunoassay methods. Serum FGF-23 levels were deter-
mined with a sandwich enzyme-linked immunosorbent
assay (ELISA) system that detects biologically active in-
tact human FGF-23 using 2 kinds of monoclonal anti-
bodies requiring the simultaneous presence of both the
N-terminal and C-terminal portions of FGF-23 [12]. The
interassay variation in the normal and elevated concen-
tration range was found to be <6%.
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Fig. 1. Correlations between plasma intact
PTH levels and serum calcium (Ca), inorganic
phosphate (Pi), and FGF-23 levels at the be-
ginning of the observation period. Plasma in-
tact PTH did not show significant correlation
with serum Ca, Pi, or FGF-23 levels in long-
term dialysis patients with mild secondary hy-
perparathyroidism.
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Fig. 2. Correlations between serum FGF-23
levels and serum calcium (Ca), inorganic
phosphate (Pi) levels, and Ca × Pi products at
the beginning of the observation period. The
logarithmic number of serum FGF-23 levels
showed significant correlations with Ca, Pi,
and Ca × Pi in long-term dialysis patients with
mild secondary hyperparathyroidism.
Data and statistical analyses
Data are expressed as mean ± SD, and P < 0.05
is regarded as significant. Differences between groups
were calculated by the Mann-Whitney test. As for the
simple correlation studies, the correlation coefficients
were calculated by the method of Pearson. A logistic
regression method was applied to sort out the factors
that significantly affect the prognosis of secondary hy-
perparathyroidism. Analyses using the receiver-operated
characteristic (ROC) curves were carried out to deter-
mine the usefulness of each screening test for discrim-
inating patients with secondary hyperparathyroidism
refractory to medical therapy [13, 14]. Paired t tests were
applied to compare each area under curve (AUC) ob-
tained by ROC. The computations were carried out on
an Apple Macintosh computer type G4 with StatView
version 5.0 software (SAS, Cary, NC, USA).
Detection of fgf-23 mRNA
To clarify the origin of high levels of serum FGF-
23, total RNA was purified from surgically excised
parathyroid glands or cultured cells, or iliac bone biopsy
specimen from another group of patients with very
severe hyperparathyroidism, by using Isogen (Nippon
Gene Co., Ltd., Tokyo, Japan). Equal amounts of RNA
(1 lg) were reverse-transcribed. Reverse transcription-
polymerase chain reaction (RT-PCR) was performed us-
ing specific primers (5′-tatttcgacccggagaactg-3′ for sense
and 5′-ggtatgggggtgttgaagtg-3′ for antisense) to amplify
the 203-bp coding sequence of the human fgf-23 cDNA.
PCR reactions were carried out at 94◦C for 20 seconds,
60◦C for 45 seconds, and 72◦C for 60 seconds for 29 cycles.
RESULTS
Clinical courses
All 103 patients enrolled in the study remained sub-
jects of the study. None of them received either surgi-
cal parathyroidectomy or percutaneous ethanol injection
therapy during the observation period. The plasma in-
tact PTH levels at 2 years after sample collection were
more than 300 pg/mL in 17 of the subjects. Thus, those
17 patients were judged to have refractory secondary
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Fig. 3. Pretreatment serum FGF-23 levels and treatment with active
vitamin D agents. Of those 103 patients, 47 were receiving treatment
with active vitamin D agents, and the remaining 56 were not at the
initiation of the study period. The pretreatment FGF-23 levels were
significantly higher in patients under active vitamin D therapy. Closed
bar: patients receiving therapy with active vitamin D agents; open bar:
patients without active vitamin D agents.
hyperparathyroidism. Table 1 summarizes the clinical
features of those 17 patients and the remaining 86
patients with medically controllable secondary hyper-
parathyroidism.
Correlations between factors obtained at the beginning
of the study
Plasma intact PTH levels were distributed between 6
and 300 pg/mL. The levels showed no significant correla-
tions with Ca, Pi, or FGF-23 (Fig. 1).
Serum FGF-23 levels were distributed between 14 and
98,646 ng/L, while the standard levels obtained from
healthy volunteers were 27.8 ± 9.0 ng/L [15]. The lev-
els showed significant correlations with Ca, Pi, and Ca ×
Pi, respectively (Fig. 2). Patients under active vitamin D
treatment showed significantly higher serum FGF-23 lev-
els than did those without the therapy (Fig. 3).
Relationships between factors obtained at the beginning
of the study and the future progression of secondary
hyperparathyroidism
A logistic regression analysis was performed to detect
the factors that affect the development of secondary hy-
Table 2. A logistic regression method was applied to sort out the
factors that significantly affected the prognosis of secondary
hyperparathyroidism
P value j2 Odds ratio (95% range)
FGF-23 0.0112 6.432 2.558 (1.238–5.287)
Pi 0.1068 2.601 .556 (.273–1.135)
Intact PTH 0.1111 2.539 1.634 (.893–2.988)
Ca 0.1668 1.911 1.517 (.840–2.737)
Age 0.3627 .829 .775 (.448–1.341)
Dialysis 0.3866 .750 1.248 (.756–2.059)
OC 0.5612 .338 1.201 (.647–2.229)
bAP 0.8223 .050 1.059 (.640–1.753)
Abbreviations: OC, intact osteocalcin; bAP, serum bone-specific alkaline
phosphatase. Serum levels of FGF-23 were the only independent variable that
significantly affected the prognosis.
perparathyroidism. The results showed that only serum
levels of FGF-23 significantly affected the prognosis
(Table 2).
Patients who were judged to have refractory secondary
hyperparathyroidism had presented significantly higher
serum levels of FGF-23 than did those with medically con-
trollable secondary hyperparathyroidism 2 years before
the judgment, whereas plasma intact PTH levels were
comparable between the 2 groups (Fig. 4).
The FGF-23 levels were significantly correlated with
the delta intact PTH, which was defined as follows: intact
PTH levels at 2 years after sample collection for intact
FGF-23 measurement − intact PTH levels at sample col-
lection for FGF-23 measurement (Fig. 5).
The prediction of refractory secondary
hyperparathyroidism
Analyses using the ROC curves demonstrated that the
area under the curves (AUC) obtained from FGF-23
(7099.9) was significantly greater than that obtained from
intact PTH (6306.4, P < 0.01) or Ca × Pi (5670.3, P <
0.0001) (Fig. 6).
The ROC analysis revealed that the highest sensitivity
× specificity product was obtained when the discrimi-
nating point was set at FGF-23 level = 7554 ng/L, the
specificity was 52.9%, and the sensitivity was 74.4% at
the point.
The patients were divided into 2 groups, the high FGF-
23 (FGF-23 ≥7500 ng/L) group and the low FGF-23
(FGF-23 <7500 ng/L) group. The plasma intact PTH lev-
els at the beginning of the observation period were com-
parable between the 2 groups (Fig. 7). Although levels in
many patients overlapped (Fig. 8), the intact PTH levels
at 2 years after the sample collection were significantly
higher in the high FGF-23 group than were those in the
low FGF-23 group (Fig. 7).
Origins of high levels of FGF-23
The expression of fgf-23 mRNA was detected in iliac
bone samples in a dialysis patient with severe secondary
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Fig. 4. Plasma intact PTH levels and serum
FGF-23 levels before the observation period.
Patients who would be judged to have refrac-
tory secondary hyperparathyroidism 2 years
after the sample collection had presented sig-
nificantly higher serum levels of FGF-23 than
did those who developed medically control-
lable secondary hyperparathyroidism. How-
ever, their plasma intact PTH levels were
scarcely different.
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Fig. 5. Serum FGF-23 levels and the change of plasma intact PTH
levels. The higher the serum FGF-23 levels had been, the more the
plasma intact PTH levels increased in the 2 years of the study period.
delta intact PTH = (plasma intact PTH levels 2 years after the sample
collection for the determination of serum FGF-23 levels) − (plasma
intact PTH levels at the sample collection).
hyperparathyroidism. However, the expression was not
detected in parathyroid glands extracted from those with
severe secondary hyperparathyroidism (Fig. 9).
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Fig. 6. The receiver-operated characteristic curves. The area under the
curve obtained with FGF-23 (7099.9) was significantly greater than that
with intact PTH (6306.4, P < 0.01) or Ca × Pi (5670.3, P < 0.0001).
DISCUSSION
The aim of the present study was to identify the fac-
tors that discriminate those patients with mild secondary
hyperparathyroidism who will become resistant to med-
ical therapy 2 years after the prediction. Such factors
might not be indicators of the present severity of sec-
ondary hyperparathyroidism. Although this study was
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Fig. 7. Plasma intact PTH levels in patients
with FGF-23 ≥7500 ng/L and FGF-23 <7500
ng/L. Patients with serum intact FGF-23 levels
≤7500 ng/L showed significantly higher levels
of plasma intact PTH 2 years after the sam-
ple collection than did those with <7500 ng/L.
However, plasma intact PTH levels were com-
parable between the 2 groups at the beginning
of the observation period.
carried out in a limited number of patients, it revealed
that serum FGF-23 levels were such a potential predictor
in long-term dialysis patients with mild secondary hyper-
parathyroidism. The levels alone may not be enough to
discriminate secondary hyperparathyroidism resistant to
medical therapy; however, the information can help clini-
cians to establish a treatment strategy. Thus, the measure-
ment of serum FGF-23 levels is a promising laboratory
examination for treating patients with uremic secondary
hyperparathyroidism. Circulating Pi, OC, or bAP levels
were not found to be suitable for this purpose in this
study.
FGF-23 is a natural circulating phosphaturic factor
[16–18] that was discovered in a sample obtained from
patients with autosomal-dominant hereditary rickets [8]
and tumor-related osteomalacia [9]. Circulating FGF-
23 seems to play a role in the regulation of phospha-
turesis and vitamin D 1-a hydroxylase activity [17–21].
Even though these known physiologic actions are per-
formed in the kidney, it is unknown whether circulating
FGF-23 demonstrates bioactivities in long-term dialysis
patients.
Circulating FGF-23 levels are elevated in patients with
chronic renal failure [10, 15, 22]. Two groups have re-
ported that the elevation of circulating FGF-23 in dialysis
patients is in part derived from the accumulation of the
degraded fragments, which were detectable by c-terminal
FGF-23 assay kits [10, 23]. By contrast, the assay kit ap-
plied in this study detects only the bioactive form of intact
FGF-23. The measured values of intact FGF-23 levels
were distributed in a wide range, and it was, therefore,
quite unlikely that decreased renal excretion of either the
degraded or intact form of FGF-23 molecules was the ma-
jor determinant of circulating FGF-23 levels in this study.
The cause of the increased circulating FGF-23 levels
in dialysis patients remains obscure. Weber has reported
that Ca × Pi products correlate with serum FGF-23 levels
in patients with end-stage renal disease [9], and our data
generally agree with these results. Bone is a likely source
of circulating FGF-23 [24, 25], and circulating PTH levels
may affect FGF-23 production in osteoblastic cells [25]. In
fact, the expression of fgf-23 mRNA was detected in iliac
bone sample obtained from a dialysis patient with severe
secondary hyperparathyroidism (Fig. 9A). Active vita-
min D therapy is another possible factor that increases
serum FGF-23 levels in dialysis patients (Fig. 3). Circu-
lating FGF-23 levels may represent mineral and parathy-
roid metabolism; however, the direct correlation between
FGF-23 levels and Ca, Pi, and intact PTH levels was
rather weak in this study (Fig. 2).
This study may have failed to show a positive corre-
lation between serum FGF-23 and plasma intact PTH
levels because the pretreatment intact PTH levels were
confined to a narrow range of 6 to 300 pg/mL. Thus,
we do not intend to neglect the finding previously re-
ported by Larsson [21]. Nevertheless, serum FGF-23
levels predicted the future development of secondary
hyperparathyroidism better than did any of other fac-
tors. We once hypothesized that biologically transformed
parathyroid cells might produce FGF-23 because serum
FGF-23 levels decreased gradually after surgical parathy-
roidectomy in dialysis patients [26]; however, the fgf-23
mRNA expression has not been documented in nodu-
lar hyperplastic parathyroid glands ex vivo (Fig. 9B).
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Fig. 8. The logarithmic numbers of pretreatment serum FGF-23 lev-
els. Closed circles: patients with secondary hyperparathyroidism con-
trollable by medical therapies; open circles: patients with secondary
hyperparathyroidism refractory to medical therapies. Although the
mean FGF-23 level was significantly different between groups (Fig. 4),
there were a number of patients in the overlapping area.
Further studies are necessary to reveal the mechanism
of increased serum FGF-23 levels and their pathophysi-
ologic role in dialysis patients.
CONCLUSION
Serum levels of FGF-23 were a useful factor to predict
the future development of refractory secondary hyper-
parathyroidism. The measurement of serum FGF-23 lev-
els is a promising laboratory method that can be applied
in clinical practice for the treatment of patients with ure-
mic secondary hyperparathyroidism. Prospective studies
and elucidation of mechanisms are certainly needed in
the near future.
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Fig. 9. RT-PCR analysis of fgf-23 mRNA expression. (A) The expres-
sion of fgf-23 mRNA in iliac bone and parathyroid samples obtained
from a patient with severe secondary hyperparathyroidism (66 years
old, female, intact PTH: 1126 pg/mL, FGF-23: 61,814 ng/L). (B) The
expression of fgf-23 mRNA in nodular hyperplastic parathyroid glands
extracted from patients with severe secondary hyperparathyroidism.
Peak cells (+): PEAK Rapid cells (Edge Biosystems, Gaithersburg,
MD, USA) transfected with pEAK8 vector containing full-length hu-
man FGF-23, as the positive control. Patient 1: 48 years old, male, intact
PTH: 1150 pg/mL, FGF-23: 83,230 ng/L. Patient 2: 65 years old, female,
intact PTH: 980 pg/mL, FGF-23: 60,320 ng/L. Patient 3: 32 years old,
male, intact PTH: 1750 pg/mL, FGF-23: 111,362 ng/L. Peak cell (−):
Mock-transfected PEAK Rapid cells as the negative control.
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